International AIDS society conference 2023 summary

HIV Med. 2024 Feb;25(2):168-173. doi: 10.1111/hiv.13563. Epub 2023 Oct 23.

Abstract

Aim: This article summarizes key research presented at the International AIDS Society (IAS) Conference in Brisbane, held in July 2023.

Co-morbidities: The REPRIEVE Trial as a conference highlight, demonstrating significantly fewer major cardiovascular events amongst people with HIV who were randomized to pitavastatin compared to placebo. Key data on weight, hypertension and incident diabetes are also summarized.

Antiretroviral therapy: Novel data on doravirine and islatravir are described as are trials demonstrating efficacy dolutegravir/lamivudine first-line in people without baseline resistance testing and in suppressed switch amongst people with historic lamivudine resistance.

Hiv cure: The sixth case of HIV cure secondary to stem cell transplantation is summarized, as are new insights into the central nervous system as an HIV reservoir.

Keywords: HIV; IAS; antiretroviral; co-morbidities; conference; cure.

Publication types

  • Congress

MeSH terms

  • Acquired Immunodeficiency Syndrome* / drug therapy
  • Anti-HIV Agents / therapeutic use
  • HIV Infections* / drug therapy
  • Humans
  • Lamivudine / therapeutic use
  • Randomized Controlled Trials as Topic

Substances

  • Anti-HIV Agents
  • Lamivudine